Research progress of sacubitril/valsartan in heart failure patients with preserved ejection fraction

doi:10.5246/jcps.2022.06.041

Abstract

Abstract:

With the launch of sacubitril/valsartan (ARNI), there are new options for the treatment of heart failure (HF). However, ARNI is currently only used in HF patients with reduced ejection fraction (HFrEF). No evidence shows that no modern treatment can reduce mortality in HF patients with preserved ejection fraction (HFpEF). Therefore, it is urgently necessary clarify whether ARNI can be used in the treatment of HFpEF. In the present study, we summarized the research progress of ARNI in the treatment of HFpEF.

Key words: Preserved ejection fraction, Reduced ejection fraction, Sacubitril/valsartan

Supporting:

Jingjing Cao, Shujuan Zhao, Chenglong Zhao, Peizhi Ma. Research progress of sacubitril/valsartan in heart failure patients with preserved ejection fraction[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(6): 471-477.

References 30

[1]	Roth, G.A.; Johnson, C.; Abajobir, A.; Abd-Allah, F.; Abera, S.F.; Abyu, G.; Ahmed, M.; Aksut, B.; Alam, T.; Alam, K.; Alla, F.; Alvis-Guzman, N.; Amrock, S.; Ansari, H.; Ärnlöv, J.; Asayesh, H.; Atey, T.M.; Avila-Burgos, L.; Murray, C. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 2017, 70, 1–25.
[2]	Members, W.G.; Mozaffarian, D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman, M.; Das, S.R.; de Ferranti, S.; Després, J.P.; Fullerton, H.J.; Howard, V.J.; Huffman, M.D.; Isasi, C.R.; Jiménez, M.C.; Judd, S.E.; Kissela, B.M.; Lichtman, J.H.; Lisabeth, L.D.; Liu, S.M.; Mackey, R.H.; Magid, D.J.; McGuire, D.K.; Mohler, E.R.; Moy, C.S.; Muntner, P.; Mussolino, M.E.; Nasir, K.; Neumar, R.W.; Nichol, G.; Palaniappan, L.; Pandey, D.K.; Reeves, M.J.; Rodriguez, C.J.; Rosamond, W.; Sorlie, P.D.; Stein, J.; Towfighi, A.; Turan, T.; Virani, S.S.; Woo, D.; Yeh, R.W.; Turner, M.B.; Committee, A.H.A.S.; Subcommittee, S.S. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation. 2016, 133, e38–e360.
[3]	McMurray, J.J.V.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.R.; Investigators, P.H.C.A. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur. J. Heart Fail. 2013, 15, 1062–1073.
[4]	Jessup, M. Neprilysin inhibition: a novel therapy for heart failure. N. Engl. J. Med. 2014, 371, 1062–1064.
[5]	Yandrapalli, S.; Aronow, W.S.; Mondal, P.; Chabbott, D.R. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Arch. Med. Sci. 2017, 13, 1207–1216.
[6]	Jessup, M. Neprilysin inhibition: a novel therapy for heart failure. N. Engl. J. Med. 2014, 371, 1062–1064.
[7]	Lang, C.C.; Struthers, A.D. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat. Rev. Cardiol. 2013, 10, 125–134.
[8]	Gori, M.; D'Elia, E.; Senni, M. Sacubitril/valsartan therapeutic strategy in HFpEF: clinical insights and perspectives. Int. J. Cardiol. 2019, 281, 158–165.
[9]	Owan, T.E.; Hodge, D.O.; Herges, R.M.; Jacobsen, S.J.; Roger, V.L.; Redfield, M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006, 355, 251–259.
[10]	Senni, M.; Paulus, W.J.; Gavazzi, A.; Fraser, A.G.; Díez, J.; Solomon, S.D.; Smiseth, O.A.; Guazzi, M.; Lam, C.S.P.; Maggioni, A.P.; Tschöpe, C.; Metra, M.; Hummel, S.L.; Edelmann, F.; Ambrosio, G.; Stewart Coats, A.J.; Filippatos, G.S.; Gheorghiade, M.; Anker, S.D.; Levy, D.; Pfeffer, M.A.; Stough, W.G.; Pieske, B.M. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur. Heart J. 2014, 35, 2797–2815.
[11]	D’Elia, E.; Vaduganathan, M.; Gori, M.; Gavazzi, A.; Butler, J.; Senni, M. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur. J. Heart Fail. 2015, 17, 1231–1239.
[12]	Hamdani, N.; Bishu, K.G.; von Frieling-Salewsky, M.; Redfield, M.M.; Linke, W.A. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc. Res. 2012, 97, 464–471.
[13]	van Heerebeek, L.; Hamdani, N.; Falcão-Pires, I.; Leite-Moreira, A.F.; Begieneman, M.P.V.; Bronzwaer, J.G.F.; van der Velden, J.; Stienen, G.J.M.; Laarman, G.J.; Somsen, A.; Verheugt, F.W.A.; Niessen, H.W.M.; Paulus, W.J. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012, 126, 830–839.
[14]	Krüger, M.; Kötter, S.; Grützner, A.; Lang, P.; Andresen, C.; Redfield, M.M.; Butt, E.; dos Remedios, C.G.; Linke, W.A. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ. Res. 2009, 104, 87–94.
[15]	Paulus, W.J.; Tschöpe, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013, 62, 263–271.
[16]	Franssen, C.; Chen, S.; Unger, A.; Korkmaz, H.I.; de Keulenaer, G.W.; Tschöpe, C.; Leite-Moreira, A.F.; Musters, R.; Niessen, H.W.M.; Linke, W.A.; Paulus, W.J.; Hamdani, N. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016, 4, 312–324.
[17]	Ahluwalia, A.; MacAllister, R.J.; Hobbs, A.J. Vascular actions of natriuretic peptides. Basic Res. Cardiol. 2004, 99, 83–89.
[18]	Shaw, R.M.; Nikolova, A.P. A surprising noncanonical role for calcineurin in pressure-induced cardiac hypertrophy. J. Am. Coll. Cardiol. 2018, 71, 668–669.
[19]	Gu, J.; Noe, A.; Chandra, P.; Al-Fayoumi, S.; Ligueros-Saylan, M.; Sarangapani, R.; Maahs, S.; Ksander, G.; Rigel, D.F.; Jeng, A.Y.; Lin, T.H.; Zheng, W.Y.; Dole, W.P. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor—neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 2010, 50, 401–414.
[20]	Hinson, J.P.; Kapas, S.; Smith, D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr. Rev. 2000, 21, 138–167.
[21]	Lisy, O.; Jougasaki, M.; Schirger, J.A.; Chen, H.H.; Barclay, P.T.; Burnett, J.C. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am. J. Physiol. 1998, 275, F410–F414.
[22]	Machado, J.; Manfredi, L.H.; Silveira, W.A.; Gonçalves, D.A.P.; Lustrino, D.; Zanon, N.M.; Kettelhut, I.C.; Navegantes, L.C. Calcitonin gene-related peptide inhibits autophagic-lysosomal proteolysis through cAMP/PKA signaling in rat skeletal muscles. Int. J. Biochem. Cell Biol. 2016, 72, 40–50.
[23]	Cruden, N.L.M.; Witherow, F.N.; Webb, D.J.; Fox, K.A.A.; Newby, D.E. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1043–1048.
[24]	Nilsson, C.; Hansen, T.K.; Rosenquist, C.; Hartmann, B.; Kodra, J.T.; Lau, J.F.; Clausen, T.R.; Raun, K.; Sams, A. Long acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1. Eur. J. Pharmacol. 2016, 773, 24–31.
[25]	Kario, K.; Sun, N.L.; Chiang, F.T.; Supasyndh, O.; Baek, S.H.; Inubushi-Molessa, A.; Zhang, Y.; Gotou, H.; Lefkowitz, M.; Zhang, J. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014, 63, 698–705.
[26]	Mitchell, G.F.; Izzo, J.L.; Lacourcière, Y.; Ouellet, J.P.; Neutel, J.; Qian, C.L.; Kerwin, L.J.; Block, A.J.; Pfeffer, M.A. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation. 2002, 105, 2955–2961.
[27]	Williams, B.; Cockcroft, J.R.; Kario, K.; Zappe, D.H.; Brunel, P.C.; Wang, Q.; Guo, W.N. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension. 2017, 69, 411–420.
[28]	Solomon, S.D.; Zile, M.; Pieske, B.; Voors, A.; Shah, A.; Kraigher-Krainer, E.; Shi, V.; Bransford, T.; Takeuchi, M.; Gong, J.J.; Lefkowitz, M.; Packer, M.; McMurray, J.J.;. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012, 380, 1387–1395.
[29]	Modin, D.; Andersen, D.M.; Biering-Sørensen, T. Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides? Echo Res. Pract. 2018, 5, R65–R79.
[30]	Scott, D.; Solomon, John J.V.; McMurray, Inder S.; Anand, D.; Phil,Junbo Ge.; Carolyn S.P.L. Rouleau Angiotensin-Neprilysin Inhibition in Hear Failure with Preserved Ejection Fraction. New England J. Med. 2019, 1, 1–11.